{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T08:31:10Z","timestamp":1696926670513},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelosuppression and associated immunosuppression are major problems in cancer chemotherapy. Thus, infection remains a significant source of morbidity and mortality during chemotherapy of cancer patients. Viral infections, particularly herpes simplex virus, varicella zoster virus, and cytomegalovirus, result either due to reactivation of latent viruses or new infections as sequelae of chemotherapy and debilitated cell-mediated immunity. Ultimately, the resolution of these infections can only be achieved after the control of malignancy and regaining the patient's ability to mount adequate immune responses. We show here that EM011, a tubulin-binding, nontoxic, orally available anticancer agent, does not alter absolute CD4+, CD8+, B220+, and NK1.1+ cell counts in immunocompetent mice. More importantly, EM011 treatment at tumor-suppressive dosages (300 mg\/kg) does not suppress cell-mediated immune responses in mice experimentally challenged with acute lymphocytic choriomeningitis virus infection, in that mice mount robust virus-specific CD8+ and CD4+ T-cell immune responses while maintained on daily drug treatment. Thus, CD8+ and CD4+ T-cell expansion and acquisition of effector functions is not perturbed by EM011 treatment. These data provide compelling evidence to support the nonimmunosuppressive nature of EM011 therapy and provide strong impetus for combining chemotherapy with immunotherapy as a novel anticancer strategy. [Mol Cancer Ther 2007;6(11):2891\u20139]<\/jats:p>","DOI":"10.1158\/1535-7163.mct-07-0359","type":"journal-article","created":{"date-parts":[[2007,11,19]],"date-time":"2007-11-19T20:43:20Z","timestamp":1195505000000},"page":"2891-2899","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nonimmunosuppressive chemotherapy: EM011-treated mice mount normal T-cell responses to an acute lymphocytic choriomeningitis virus infection"],"prefix":"10.1158","volume":"6","author":[{"given":"Ritu","family":"Aneja","sequence":"first","affiliation":[{"name":"1Laboratory for Drug Discovery, Design, and Research, Department of Cell Biology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Kalia","sequence":"additional","affiliation":[{"name":"2Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafi","family":"Ahmed","sequence":"additional","affiliation":[{"name":"2Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish C.","family":"Joshi","sequence":"additional","affiliation":[{"name":"1Laboratory for Drug Discovery, Design, and Research, Department of Cell Biology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,11,19]]},"reference":[{"key":"2022060804351185700_BIB1","unstructured":"Gallagher J. Supportive care for viral infections in cancer patients. Curr Opin Oncol\u20081991;3:643\u20137."},{"key":"2022060804351185700_BIB2","doi-asserted-by":"crossref","unstructured":"Devine SM, Wingard JR. Viral infections in severely immunocompromised cancer patients. Support Care Cancer\u20081994;2:355\u201368.","DOI":"10.1007\/BF00344048"},{"key":"2022060804351185700_BIB3","doi-asserted-by":"crossref","unstructured":"Joo HG. Altered maturation of dendritic cells by Taxol, an anticancer drug. J Vet Sci\u20082003;4:229\u201334.","DOI":"10.4142\/jvs.2003.4.3.229"},{"key":"2022060804351185700_BIB4","doi-asserted-by":"crossref","unstructured":"Lee M, Yea SS, Jeon YJ. Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol\u20082000;22:615\u201321.","DOI":"10.1016\/S0192-0561(00)00024-2"},{"key":"2022060804351185700_BIB5","unstructured":"Horwitz S, Cohen BD, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr\u20081993;15:55\u201361."},{"key":"2022060804351185700_BIB6","unstructured":"Chabner BA, Horwitz SB, Clendennin NJ, Purvis JD. Vinca alkaloids. Cancer Chemother Biol Response Modif\u20081991;12:67\u201373."},{"key":"2022060804351185700_BIB7","doi-asserted-by":"crossref","unstructured":"Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents\u20082005;5:65\u201371.","DOI":"10.2174\/1568011053352569"},{"key":"2022060804351185700_BIB8","doi-asserted-by":"crossref","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer\u20082004;4:253\u201365.","DOI":"10.1038\/nrc1317"},{"key":"2022060804351185700_BIB9","doi-asserted-by":"crossref","unstructured":"Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med\u20081997;8:353\u201374.","DOI":"10.1146\/annurev.med.48.1.353"},{"key":"2022060804351185700_BIB10","doi-asserted-by":"crossref","unstructured":"Pace A, Bove L, Nistico C, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry\u20081996;61:409\u201311.","DOI":"10.1136\/jnnp.61.4.409"},{"key":"2022060804351185700_BIB11","doi-asserted-by":"crossref","unstructured":"Theiss C, Meller M. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res\u20082000;299:213\u201324.","DOI":"10.1007\/s004410050019"},{"key":"2022060804351185700_BIB12","doi-asserted-by":"crossref","unstructured":"Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol\u20082000;424:563\u201376.","DOI":"10.1002\/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U"},{"key":"2022060804351185700_BIB13","doi-asserted-by":"crossref","unstructured":"Zhou J, Gupta K, Aggarwal S, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol\u20082003;63:799\u2013807.","DOI":"10.1124\/mol.63.4.799"},{"key":"2022060804351185700_BIB14","doi-asserted-by":"crossref","unstructured":"Aneja R, Vangapandu SN, Lopus M, et al. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol\u20082003;72:415\u201326.","DOI":"10.1016\/j.bcp.2006.05.004"},{"key":"2022060804351185700_BIB15","doi-asserted-by":"crossref","unstructured":"Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood\u20082003;107:2486\u201392.","DOI":"10.1182\/blood-2005-08-3516"},{"key":"2022060804351185700_BIB16","unstructured":"Landen JW, Lang R, McMahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res\u20082003;62:4109\u201314."},{"key":"2022060804351185700_BIB17","doi-asserted-by":"crossref","unstructured":"Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther\u20082006;5:2366\u201377.","DOI":"10.1158\/1535-7163.MCT-06-0205"},{"key":"2022060804351185700_BIB18","doi-asserted-by":"crossref","unstructured":"Oldstone MB, Blount P, Southern PJ, Lampert PW. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature\u20081986;321:239\u201343.","DOI":"10.1038\/321239a0"},{"key":"2022060804351185700_BIB19","doi-asserted-by":"crossref","unstructured":"Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MBA. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med\u20081984;160:521\u201340.","DOI":"10.1084\/jem.160.2.521"},{"key":"2022060804351185700_BIB20","doi-asserted-by":"crossref","unstructured":"Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity\u20081998;8:177\u201387.","DOI":"10.1016\/S1074-7613(00)80470-7"},{"key":"2022060804351185700_BIB21","doi-asserted-by":"crossref","unstructured":"Grayson JM, Zajac AJ, Altman JD, Ahmed R. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J Immunol\u20082000;164:3950.","DOI":"10.4049\/jimmunol.164.8.3950"},{"key":"2022060804351185700_BIB22","doi-asserted-by":"crossref","unstructured":"Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity\u20081998;8:363.","DOI":"10.1016\/S1074-7613(00)80541-5"},{"key":"2022060804351185700_BIB23","doi-asserted-by":"crossref","unstructured":"Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol\u20082002;2:251\u201362.","DOI":"10.1038\/nri778"},{"key":"2022060804351185700_BIB24","doi-asserted-by":"crossref","unstructured":"Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol\u20082004;78:5535\u201345.","DOI":"10.1128\/JVI.78.11.5535-5545.2004"},{"key":"2022060804351185700_BIB25","doi-asserted-by":"crossref","unstructured":"Matloubian M, Kolhekar SR, Somasundaram T, Ahmed R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J Virol\u20081993;67:7340\u20139.","DOI":"10.1128\/jvi.67.12.7340-7349.1993"},{"key":"2022060804351185700_BIB26","doi-asserted-by":"crossref","unstructured":"Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol\u20081994;68:8056\u201363.","DOI":"10.1128\/jvi.68.12.8056-8063.1994"},{"key":"2022060804351185700_BIB27","doi-asserted-by":"crossref","unstructured":"Blattman JN, Antia R, Soudive DJD, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med\u20082002;195:657\u201364.","DOI":"10.1084\/jem.20001021"},{"key":"2022060804351185700_BIB28","doi-asserted-by":"crossref","unstructured":"Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human \u03b1\u03b2 T cell receptor diversity. Science\u20081999;286:958\u201361.","DOI":"10.1126\/science.286.5441.958"},{"key":"2022060804351185700_BIB29","doi-asserted-by":"crossref","unstructured":"Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med\u20081998;187:1395\u2013402.","DOI":"10.1084\/jem.187.9.1395"},{"key":"2022060804351185700_BIB30","doi-asserted-by":"crossref","unstructured":"Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science\u20081996;274:94\u20136.","DOI":"10.1126\/science.274.5284.94"},{"key":"2022060804351185700_BIB31","doi-asserted-by":"crossref","unstructured":"Bachmann MF, Barner M, Viola A, Kopf M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol\u20081999;29:291\u20139.","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K"},{"key":"2022060804351185700_BIB32","doi-asserted-by":"crossref","unstructured":"Cerwenka A, Morgan TM, Dutton RW. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol\u20081999;163:5535\u201343.","DOI":"10.4049\/jimmunol.163.10.5535"},{"key":"2022060804351185700_BIB33","doi-asserted-by":"crossref","unstructured":"Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell\u20082002;111:837\u201351.","DOI":"10.1016\/S0092-8674(02)01139-X"},{"key":"2022060804351185700_BIB34","doi-asserted-by":"crossref","unstructured":"Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol\u20082003;4:225\u201334.","DOI":"10.1038\/ni889"},{"key":"2022060804351185700_BIB35","doi-asserted-by":"crossref","unstructured":"Kaech SM, Ahmed R. Memory CD8+ T-cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol\u20082001;2:415\u201322.","DOI":"10.1038\/87720"},{"key":"2022060804351185700_BIB36","doi-asserted-by":"crossref","unstructured":"van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol\u20082001;2:423\u20139.","DOI":"10.1038\/87730"},{"key":"2022060804351185700_BIB37","doi-asserted-by":"crossref","unstructured":"Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early programming of T-cell populations responding to bacterial infection. J Immunol\u20082000;165:6833\u20139.","DOI":"10.4049\/jimmunol.165.12.6833"},{"key":"2022060804351185700_BIB38","doi-asserted-by":"crossref","unstructured":"Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity\u20081998;8:89\u201395.","DOI":"10.1016\/S1074-7613(00)80461-6"},{"key":"2022060804351185700_BIB39","doi-asserted-by":"crossref","unstructured":"Jelley-Gibbs DM, Lepak NM, Yen M, Swain SL. Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation. J Immunol\u20082000;165:5017\u201326.","DOI":"10.4049\/jimmunol.165.9.5017"},{"key":"2022060804351185700_BIB40","doi-asserted-by":"crossref","unstructured":"Iezzi G, Scotet E, Scheidegger D, Lanzavecchia A. The interplay between the duration of TCR and cytokine signaling determines T-cell polarization. Eur J Immunol\u20081999;29:4092\u2013101.","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<4092::AID-IMMU4092>3.0.CO;2-A"},{"key":"2022060804351185700_BIB41","doi-asserted-by":"crossref","unstructured":"Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science\u20081998;281:1322.","DOI":"10.1126\/science.281.5381.1322"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/6\/11\/2891\/1874640\/2891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/6\/11\/2891\/1874640\/2891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T20:55:31Z","timestamp":1684097731000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/6\/11\/2891\/234946\/Nonimmunosuppressive-chemotherapy-EM011-treated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2007,11,19]]},"published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-07-0359","relation":{},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,1]]}}}